Wilbanks Smith & Thomas Asset Management LLC Neurocrine Biosciences Inc Transaction History

Wilbanks Smith & Thomas Asset Management LLC

$3.54 Billion
Q1 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2018 Feb 08, 2019	SELL	$68.32 - $124.36 $13,322 - $24,250	-195 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $19,281 - $24,540	195 New	195 $24,000

Others Institutions Holding NBIX

# of Institutions

622

Shares Held

95.2M

Call Options Held

661K

Put Options Held

221K

Black Rock Inc. New York, NY

14.2M
Shares

$1.73 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

10.1M
Shares

$1.23 Billion
0.03% of portfolio
State Street Corp Boston, MA

4.61M
Shares

$563 Million
0.03% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

2.47M
Shares

$302 Million
0.6% of portfolio
Jpmorgan Chase & CO New York, NY

2.36M
Shares

$289 Million
0.03% of portfolio

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.7B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wilbanks Smith & Thomas Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wilbanks Smith & Thomas Asset Management LLC with notifications on news.

Account